Immunic, Inc.
IMUXNASDAQHealthcareBiotechnology
Regular session
$16.58
+$0.08 · +0.48%
IMUX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
33
Expensive
Momentum
61
Gaining
Sentiment
50
Mixed
Risk resilience
50
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteImmunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Erik Lundgren
- Listed since
- Apr 17, 2014
- Employees
- 95
Market position
Day range
Current $16.58
52-week range
Current $16.58
- Open
- $16.48
- Previous close
- $16.50
- Volume
- 60.43K
- 0.26× average
- Average volume
- 235.08K
- Average daily volume
- Market cap
- 225.84M USD
- Beta
- 1.4
- Market reference 1
- 50-day average
- $14.7944
- +12.07% above average
- 200-day average
- $10.6341
- +55.91% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 68.34M USD
- P/E (TTM)
- -3.45×
- P/B (TTM)
- 5.52×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.7×
- Earnings yield
- -116.88%
- Free cash flow yield
- -103.40%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- 1456.20%
- Return on assets
- -404.01%
- Return on invested capital
- 1693.37%
Financial health
- Debt / equity
- 0×
- Current ratio
- 0.75×
- Altman Z-score
- -3.03
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 81.98M USD | 80.05M USD | 83.22M USD | 71.26M USD | 61.12M USD |
| Selling, general, and administrative | 21.25M USD | 18.01M USD | 16.01M USD | 15.26M USD | 13.3M USD |
| Operating expenses | 103.23M USD | 98.05M USD | 99.22M USD | 119.49M USD | 91.67M USD |
| Interest income | 1.04M USD | 3.39M USD | 3.08M USD | 1.04M USD | 66K USD |
| Interest expense | — | — | — | 1.04M USD | — |
| Depreciation and amortization | 168K USD | 134K USD | 111K USD | 77K USD | 85K USD |
| Operating income | −103.23M USD | −98.05M USD | −99.22M USD | −119.49M USD | −91.67M USD |
| Net income | −97.17M USD | −100.51M USD | −93.61M USD | −120.41M USD | −92.95M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 9%
- 1 beat, 9 misses, 1 met estimate
- Average EPS surprise
- -384.04%
- 11 comparable reports
- Latest EPS result
- -0.8
- Estimate -1.16 · Beat by 31.03%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$22.13
33.47% upsideIMUX news
IMUX peers
ETFs holding IMUX
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.58M0.00%2.3T USD0.03%$376.87-0.36%
Vanguard Extended Market ETFVXF2.22M0.00%93.7B USD0.05%$243.1-0.99%
iShares Micro-Cap ETFIWC790K0.05%1.53B USD0.60%$196.69-0.73%
Simplify Propel Opportunities ETFSURI506.96K0.60%85.05M USD2.82%$19.81-0.04%
ALPS Medical Breakthroughs ETFSBIO264.78K0.11%236.37M USD0.50%$68.61-0.72%
Avantis U.S. Small Cap Equity ETFAVSC168.82K0.01%3.16B USD0.25%$73.415-0.58%
Invesco NASDAQ Future Gen 200 ETFQQQS123.35K0.54%22.98M USD0.20%$44.44-1.43%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 5.58M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $376.87-0.36%
Vanguard Extended Market ETFVXF- Market value
- 2.22M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.1-0.99%
iShares Micro-Cap ETFIWC- Market value
- 790K
- Weight
- 0.05%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $196.69-0.73%
Simplify Propel Opportunities ETFSURI- Market value
- 506.96K
- Weight
- 0.60%
- AUM
- 85.05M USD
- Expense ratio
- 2.82%
- Price / 1D
- $19.81-0.04%
ALPS Medical Breakthroughs ETFSBIO- Market value
- 264.78K
- Weight
- 0.11%
- AUM
- 236.37M USD
- Expense ratio
- 0.50%
- Price / 1D
- $68.61-0.72%
Avantis U.S. Small Cap Equity ETFAVSC- Market value
- 168.82K
- Weight
- 0.01%
- AUM
- 3.16B USD
- Expense ratio
- 0.25%
- Price / 1D
- $73.415-0.58%
Invesco NASDAQ Future Gen 200 ETFQQQS- Market value
- 123.35K
- Weight
- 0.54%
- AUM
- 22.98M USD
- Expense ratio
- 0.20%
- Price / 1D
- $44.44-1.43%
Continue in GoAI
Research IMUXresearch.disclaimer